Fælles hensigtserklæring om skifte mellem biologiske og biosimilære lægemidler

Tre internationale brancheorganisationer udsender en fælles hensigtserklæring om skifte mellem biologiske og biosimilære lægemidler.

Den 9. marts 2017 udsendte brancheforeningerne European Biopharmaceutical Enterprises ("EBE"), European Federation of Pharmaceutical Industries and Associations ("EFPIA") og International Federation of Pharmaceutical Manufacturers and Associations ("IFPMA") hensigtserklæringen "Considerations for physicians on switching decisions regarding biosimilars".

Heraf fremgår det bl.a. at:

  • "…any decision to switch should be made on a case-by-case basis and must be patient, disease and product specific. A "one size fits all" approach is not appropriate."
  • "Switching between biosimilars represents an unknown, and one that harbours considerable uncertainty."
  • "…the physician should retain decision-making autonomy and have unrestricted choice of products to prescribe."
Hensigtserklæringen kan læses her

Seneste nyt om Life Science

Life Science